Andrew Kadis from Cambridge Vision Technology guides us through imaging technologies for retinal biomarkers in Alzheimer's disease
The article from Open Access Government discusses the potential of retinal imaging technologies as biomarkers for Alzheimer's disease (AD). It highlights how recent advancements in imaging techniques, such as optical coherence tomography (OCT) and OCT angiography (OCTA), are being explored to detect early signs of AD through changes in the retina. These technologies can reveal microstructural changes in the retina, which correlate with AD pathology, including amyloid-beta deposits and neurodegeneration. The article explains that the retina, an extension of the central nervous system, might serve as a non-invasive window to monitor brain health. Researchers are particularly interested in how these retinal changes could predict or track the progression of AD, offering a less invasive alternative to traditional brain imaging methods like MRI or PET scans. The piece also touches on ongoing studies and the need for further research to validate these retinal biomarkers for clinical use in diagnosing and monitoring Alzheimer's disease.
Travel & Leisure
